TopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Natamycin

CAS 7681-93-8

Natamycin (CAS 7681-93-8) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 393 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
1
SOURCE DrugCentral
Adverse signals
393
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Natamycin
CAS Number
7681-93-8
UNII
8O0C852CPO
InChIKey
NCXMLFZGDNKEPB-FFPOYIOWSA-N
ChEMBL ID
CHEMBL1200656
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientnatural producttherapeutic flagtopical
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1200656 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 1 bioactivity row

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- MIC 9.129811320754717 ug.mL-1 53 -
SOURCE DrugCentral 2 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Appendicolith 18 80.897 10074458
Blood phosphorus increased 17 71.218 10050196

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
NATAMYCIN 7268 SU MTHSPL
natamycin 7268 IN RXNORM
SOURCE SIDER 24 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Chest pain natamycin LLT C0008031
Chest pain natamycin PT C0008031
Corneal opacity natamycin LLT C0010038
Corneal opacity natamycin PT C0010038
Dyspnoea natamycin LLT C0013404
Dyspnoea natamycin PT C0013404
Eye irritation natamycin LLT C0235266
Eye irritation natamycin PT C0235266
Eye oedema natamycin LLT C0743680
Eye oedema natamycin PT C0743680
Eye pain natamycin LLT C0151827
Eye pain natamycin PT C0151827
Hyperaemia natamycin LLT C0020452
Hyperaemia natamycin PT C0020452
Hypersensitivity natamycin LLT C0020517
Hypersensitivity natamycin PT C0020517
Lacrimation natamycin LLT C0423153
Lacrimation increased natamycin PT C0152227
Ocular discomfort natamycin LLT C0948595
Ocular discomfort natamycin PT C0948595
Paraesthesia natamycin LLT C0030554
Paraesthesia natamycin PT C0030554
Sensation of foreign body natamycin LLT C0423602
Sensation of foreign body natamycin PT C0423602
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Natamycin used for in pharmaceutical contexts?

Natamycin (CAS 7681-93-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Natamycin?

Natamycin has 393 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Appendicolith, Blood phosphorus increased, Eye irritation, Eye pain, Foreign body in eye. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Natamycin also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for NATAMYCIN with EU status "permitted".

What clinical phase is Natamycin in?

Natamycin is rendered with ChEMBL max phase 4 (approved).